WHO ICTRP trial
Phase II study of weekly Vinorelbine and Topotecan administration treatment for…
JPRN-UMIN000008202 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000008202 |
|---|---|
| Public title | Phase II study of weekly Vinorelbine and Topotecan administration treatment for refractory adult rhabdomyosarcoma previously treated by VAC regimen |
| Scientific title | Phase II study of weekly Vinorelbine and Topotecan administration treatment for refractory adult rhabdomyosarcoma previously treated by VAC regimen - V-TOP trial |
| Primary sponsor | National Cancer Center Hospital |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Adult rhabdomyosarcoma with prior VAC therapy |
| Interventions | Vinorelvine 20 mg/m-2 day 1, 8 Topotecan 4 mg/m-2 day 1, 8 q 3 weeks until disease progression or intorelable toxicities |
| Registration date | Jun 20, 2012 |
| Target size | 16 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: